PreprintPDF Available

Covid-19 vaccinations and all-cause mortality -a long-term differential analysis among municipalities

Authors:
Preprints and early-stage research may not have been peer reviewed yet.

Abstract and Figures

We analyse the relation between covid-19 vaccinations and all-cause-mortality in N=340 Dutch municipalities (17.3M people, ~99% of population), during the entire pandemic period. We do not use covid-19-attributed mortality, mortality predictions and excess mortality, thereby bypassing the ambiguities of case-identification and mortality-modeling. Municipal demographics such as age, culture and population density are strong confounders of mortality and vaccine-uptake. We account for these by normalizing results to prepandemic year 2019, where covid was absent but demographics were highly representative for later years. Normalized to 2019, we found no correlation between municipal mortality in 2020 with vaccination uptake in 2021, which shows the effectiveness of our confounder accounting. We could not observe a mortality-reducing effect of vaccination in Dutch municipalities after vaccination and booster campaigns. We did find a 4-sigma-significant mortality-enhancing effect during the two periods of high unexplained excess mortality. Our results add to other recent findings of zero mRna-vaccine effectiveness on all-cause mortality, calling for more research on this topic.
Content may be subject to copyright.
Covid-19 vaccinations and all-cause mortality - a long-term dierential
analysis among municipalities"
André Redert, PhD"
Independent researcher"
Rodotti, Netherlands"
Abstract
We analyse the relation between covid-19 vaccinations and all-cause-mortality in N=340 Dutch
municipalities (17.3M people, ~99% of population), during the entire pandemic period. We do not
use covid-19-attributed mortality, mortality predictions and excess mortality, thereby bypassing
the ambiguities of case-identification and mortality-modeling."
#Municipal demographics such as age, culture and population density are strong confounders
of mortality and vaccine-uptake. We account for these by normalizing results to prepandemic year
2019, where covid was absent but demographics were highly representative for later years.
Normalized to 2019, we found no correlation between municipal mortality in 2020 with vaccination
uptake in 2021, which shows the eectiveness of our confounder accounting."
#We could not observe a mortality-reducing eect of vaccination in Dutch municipalities after
vaccination and booster campaigns. We did find a 4-sigma-significant mortality-enhancing eect
during the two periods of high unexplained excess mortality. Our results add to other recent
findings of zero mRna-vaccine eectiveness on all-cause mortality, calling for more research on
this topic."
Introduction
After the first covid vaccination campaign in The Netherlands, high excess mortality rates were
observed in the second half of 2021. It was known that covid variants could escape vaccine
protection [1], but the excess mortality could not be related to covid. Based on the sparse publicly
available Dutch data on excess mortality and vaccination rates, an early analysis was made
indicating a possible increased mortality in the few weeks following vaccination [2]. This inspired
Dutch parliament in December 2021 to require a more thorough analysis to be performed by the
academic world [3]. As the Dutch government did not provide medical data for this purpose, no
such analysis could be performed. In June 2022, the Dutch central bureau of statistics (CBS)
published a report [4] finding no relation between excess mortality and covid or vaccines, while
still oering no alternative explanation for the excess mortality. The academic world’s response
was critical [5]."
#In continued lack of better datasets, we performed a vaccine/mortality analysis using a dataset
that to our knowledge has not been used yet: the weekly all-cause mortality for each Dutch
municipality reported by CBS [6]. There are approximately 350 municipalities in The Netherlands,
cohorts that are very similar and clearly not suited to isolate phenomena related to age, gender or
health-status. Their usefullness comes from being similar while having slight variations in
vaccination coverage that are random/unrelated to health, e.g. due to vaccination logistics. "
#Figure 1 shows an earlier result that motivated this short report, a strong positive correlation
between vaccination coverage and mortality rate in the 2nd half of 2021. Demographics dier
across municipalities in various ways strongly aecting vaccin-uptake, see Figure 2. For covid,
age is the strongest indicator for mortality [7], which subsequently causes vaccination-
preparedness in the elderly. We will take these confounders into account by extending the
of 1 8
analysis to prepandemic year 2019, in which covid and vaccines were absent but demographics
were obviously very similar."
"
Figure 1: Preliminary result that motivated this report. Municipal vaccination-coverage and
mortality-rate correlate strongly at the end of 2021.
Figure 2: Municipal demographics provide strong counfounders such as average age, culture
(immigration) and population density, all of which aect vaccination uptake and/or mortality. All
correlation coëcients between quantities shown are in the order of ±50%.
We focus on longer-term eects of vaccination on mortality during the entire pandemic, as by now
it is clear that protective eects of vaccines against covid wane quickly and can even become
negative after about half a year, see e.g. [8,9]. We base our results only on all-cause mortality,
without reference to covid mortality, expected mortality and excess mortality. That way, we
bypass the inevitable ambiguities in covid diagnostics (death with or because of covid) and
mortality-modeling during a developing pandemic. Further, vaccines are known to have eects
beyond their target disease, recently shown specifically for covid vaccins [10], advocating for all-
cause mortality analyses."
Method
We use the following quantities, with the municipality (group), and t a time period:"
1g340
of 2 8
#All-cause mortality rate (% of municipal population) [6]"
## End-level of vaccination coverage (% of municipal population) [11]"
## Relative municipal population size (% of analysed national population) [12]"
#Proportionality scalar, our main outcome: municipal dierental of M per dierental of V
During 2019-2022, several municipalities have split and merged. In our analysis, we use only
N#=#340 municipalities that existed during the entire analysis period. This brings the total number
of people in the analysis at 17.3M, about 99% of The Netherlands. The analysis will weigh every
municipality by relative population size (the ’s sum up to exactly 1)."
#We use vaccination coverage at saturated-level reached in November 2021, for full-vaccination
of people aged 18+, rounded o to integer-valued percentages of the municipal population [11]. It
has municipal-weighted (national) mean and standard deviation of 82±5%. Non-rounded
data and/or coverage at earlier dates are not publicly available. The later booster uptake (as of
end of May 2022 [13]) correlates 96% with full-vaccination, see Figure 3, and is not additionally
informative in our analysis."
"
Figure 3: Booster coverage correlates very strongly with full-vaccination coverage, and is not
further informative in our analysis.
The essence of our approach is to regard all-cause-mortality as an N-dimensional vector
with a component for each municipality. One is free to transform any vector by rewriting it as a
weighted sum of N orthogonal basis-vectors:"
$(1)
Each of the base-vectors can be seen as a “pattern” of mortality across all municipalities, with
each the amount of that pattern occurring in or contributing to the total mortality pattern .
The first base-vector is 1g which has every component equal to 1, or equivalently, a uniform equal
Mg(t)
Vg
wg
wg
wg
Vμ
Vσ
Mg(t)
Mg(t) = K1(t)1g+K2(t) ΔVg+K3(t). . . + KN(t)Nth$base$vector
K
M
of 3 8
spread of mortality-rate across all municipalities. We choose the 2nd base-vector as , the
municipality’s deviation in vaccination coverage compared to the national weighted mean :"
$(2)
Vectors 1g and are orthogonal (their weighted inner product is zero)."
#The rationale of this approach is that the mortality rate is expected to be a quite uniform
pattern over all municipalities (first base vector 1g ), and that the remaining mortality variations will
be distributed among all other N-1 base vectors. If there is a signal present in mortality correlating
with vaccine coverage, it will manifest specifically in while other influences on mortality are
thinned out over all remaining N-2 (= 338) base vectors, improving the odds of detecting relevant
events."
#We do not have to define any of the other base-vectors 3 to N, as they are not needed to
compute the first two ’s. Solving (1) gives trivially with and defined
similarly as in (2). The is our main and only focus, from now on we will omit the 2. We obtain
its value by:"
$(3)"
The source data for [6] is given in weekly t periods. As is linear in , we can easily
recombine weekly computed values to longer or smoothed periods. As weekly data is highly
volatile, we will smooth values to a month-period by a centered, weighted moving average of 5
weeks (weights are 0.1, 0.25, 0.3, 0.25, 0.1). This lowers volatility but leaves the unit of
unchanged at mortality-rate/vaccination-coverage per week."
#We will compute from Jan 2019 to April 2022. Values before vaccination refer to correlation
of mortality with vaccination-preparedness, while values in weeks after vaccination refer to
correlation of mortality with vaccination-coverage. In the absence of confounders, an eective
vaccine will result in < 0 in the period after vaccination. Before vaccination, however, the
expectation of an eective vaccine will result in > 0, as vulnerable people are more vaccination-
prepared."
#Age and other demographics are strong confounders for mortality, covid, and vaccin-uptake,
which all bias . To detect significant values/events in , we compute mean and standard
deviation over all weeks in prepandemic year 2019, and use that as z-score :"
$(4)"
Clearly, in 2019 covid was absent but municipal demographics were very representative for the
next few years."
ΔVg
Vμ
ΔVg=VgVμVμ=
γ
wγVγ
ΔVg
1γwγΔVγ
M
K2(t)
K
K1(t) = Mμ(t)
Mμ
ΔMg
K2(t)
K(t) =
γΔMγ(t)wγΔVγ
γΔVγwγΔVγ
Mg(t)
K
ΔM
K
K
K
K
K
K
K
Kμ
Kσ
Z(t)
Z(t) = K(t)Kμ(2019wk1..52)
Kσ(2019wk1..52)
of 4 8
#One must bear in mind that refers to a ratio of dierential mortality-rate and dierential
vaccination-coverage, and one cannot extend it to an absolute relation . The dierential
eect is probably caused by a limited part of the population for which the vaccine has a
substantial eect (elderly, people with comorbidities, youngsters/adults with unlucky susceptibility
to adverse eects). When this part is accounted for, a non-linear saturation eect on mortality may
occur, for which our linear model (1) does not account."
#Our method is mathematically equivalent with computing weighted trendlines between
and , with K the resulting regression coecient. It could very well happen that at some periods
covariances between and are relatively small (<20%) and that so-called modeling-
strength R2 is in the order of a few percent. In such cases, it would be false to conclude that the
trendlines K are thus unreliable. In fact a low R2 would just reflect the relative size of a mortality-
vaccination eect amidst a much larger overall mortality rate. We will not compute R2 or similar,
instead we will use the z-score with and to determine event significance."
Results
Figure 4 shows , and an example for the period of week 50 of 2021 to get an impression
of the municipal variation."
"
Figure 4: Municipal dierences in population size, vaccination coverage and mortality rate
(example for week 50 of 2021). A subset of all 340 municipalities’ names appear on the left.
The weights have (unweighted) average 1/N (~0.29%). As there are clearly a few very large
municipalities (Amsterdam, Rotterdam, The Hague, etc) one may wonder if these will dominate the
results, eectively lowering N. The eective number of same-sized-groups in our analysis,
however, is still in the order of hundreds:"
$(5)"
K
M=K V
ΔM
ΔV
ΔM
ΔV
Kμ
Kσ
wg
Vg
Mg
wg
Neffective =egwgln wg209
of 5 8
For the example week 50 of 2021 we find:"
$(6)"
This municipal-average mortality rate corresponds to the ~4k deaths registered by the Dutch
CBS [14] (0.023% times the full Dutch population of 17.5M people)."
#The value in this period after vaccination is positive, while a negative value is expected for an
eective vaccine, in the absence of confounders. It is even about the same size as reflecting
at least a huge impact of confounders such as age. Further, the value of refers to dierential
mortality per dierential vaccination coverage, with the latter having of just 5%. The net
result is that vaccination-correlated mortality-rate is 5% of average mortality rate , or approx.
200 people in this one week. These are not 200 additional deaths related to vaccination, it means
that 200 out of 4k deaths were distributed over municipalities in the same pattern as vaccination
coverage."
#Figure 5 shows our main result, weekly values (moving monthly averages) during the
whole analysis period from Jan 2019 to Apr 2022, with our z-score using and computed
over prepandemic year 2019:"
$(7)"
For context, national prognosed, actual all-cause, and covid mortality-rates are shown, plus
primary-vaccination and booster campaigns."
"
Figure 5: Main result, K from Jan 2019 to Apr 2022 by z-score Z defined over prepandemic year
2019. Added for context are all-cause mortality, mortality prognosis (from 2020 onwards),
reported covid deaths and vaccination-coverage over time.
Mμ(2021wk50) 0.023 %
K(2021wk 50) 0.024 %
Mμ
K
Mμ
K
ΔVσ
Mμ
Z(t)
Kμ
Kσ
Kμ(2019wk152) 1.68x1040.0017 %
Kσ(2019wk152) 3.25x1050.0003 %
of 6 8
From this graphic, we observe:"
Mortality in the 1st Wuhan wave correlates extremely strong (>10 sigma) with vaccination-
preparedness, in contrast with the 2nd Alpha wave (Z ~ 0 on average, short peak at 2 sigma)
and the seasonal mortality-peak at the beginning of 2019 (-1.5 sigma)."
After the Wuhan peak, Z is significantly below zero (approx -3 sigma) for many months and
similar for Alpha wave (at -1 sigma). The average of Z over 2020 is very close to zero (~ -0.04) ,
1
meaning mortality over the entire covid-year before vaccination does not correlate with
vaccination-preparedness."
After the vaccination campaign, Z rises to +4σ at the 3rd Delta wave, then briefly dips between
Delta and Omicron waves during the booster campaign, to rise directly again to +4σ during the
much milder Omicron wave. The rises coincide with both unexplained excess mortality periods."
Conclusions
In the absence of publicly available high-quality covid/mortality/vaccination datasets in the
Netherlands, we examined the available data of municipal vaccination-coverage and weekly all-
cause mortality in a dierential approach. Although municipal variations are relatively small, the
amount of municipalities is suciently high to find significant correlations. We accounted for
strong demographic confounders (e.g. age, culture, population density) by normalizing all results
to prepandemic year 2019."
#Municipalities that suered the highest mortality during the 1st covid wave beginning of 2020
were most willing to be vaccinated later in 2021 (10 sigma). The 2nd wave in 2020 as well as the
seasonal mortality peak at beginning of 2019 did not contribute to vaccine-preparedness. Directly
after the 1st and 2nd waves a prolonged municipal mortality-rate reversal was observed, with a
net result that vaccination coverage is not correlated with total mortality from pre-vaccination year
2020. This absence of correlation reflects the eectiveness of our approach to account for
mortality-vaccination confounders, enabling the following observation to be significant."
#After both vaccination and booster campaigns, we did not observe the negative correlation
between mortality and vaccination expected for an eective vaccine. Instead, during Delta and
milder Omicron waves, correlation was significantly positive (4 sigma), coinciding exactly with the
two periods of excess mortality in The Netherlands peaking in Nov 2021 and Mar/Apr 2022."
Discussion
We could not observe a mortality-reducing eect of vaccines in Dutch municipalities, while we did
find a 4-sigma-significant mortality-enhancing eect during the two periods of high unexplained
excess mortality. These results add to recent findings of zero mRna-vaccine eectiveness on all-
cause mortality [10]."
#Clearly, our study has many shortcomings: we made use of very limited publicly available data.
Our several requests for improved data (non-rounded vaccination coverages at more time
instances) were unfortunately not granted by the Dutch government. The variability of our dataset
Proper calculation of the 2020 overall Z-value involves multiplying the found average of -0.04 by
1
the number of independent Z values in 2020, which is 52 divided by (5) applied to our weekly-to-
monthly-moving-average weights 0.1, 0.25, 0.35, 0.25, 0.1, which is 52 / 4.55 = 11.43. The
resulting Z over 2020 is approx -0.47, well below the significance limit of ±1.
of 7 8
was also limited, e.g. municipal vaccination-coverages have a spread of only ±5%. Our simple
linear model between mortality and vaccines does not capture nonlinear eects or non-uniform
populations. Especially with respect to the latter, our approach is cohortless, while covid and thus
vaccine eectiveness against mortality are highly age-dependent [7]."
#Our main result remains alarming and calls for more research on the eect of current covid
vaccines on all-cause mortality."
References
[1]#T. Kustin et al, “Evidence for increased breakthrough rates of SARS-CoV-2 variants of
concern in BNT162b2-mRNA-vaccinated individuals”, Nature, https://www.nature.com/
articles/s41591-021-01413-7"
[2]#R. Meester, W. Aukema and T. Schetters, “COVID-19 vaccinations and mortality - a
Bayesian analysis”, https://www.researchgate.net/publication/
357032975_COVID-19_vaccinations_and_mortality_-_a_Bayesian_analysis"
[3]#Tweede Kamer (Dutch parliament), https://www.tweedekamer.nl/kamerstukken/
brieven_regering/detail?id=2021Z22246&did=2021D47333"
[4]#CBS (Dutch central bureau of statistics), https://www.cbs.nl/nl-nl/nieuws/2022/25/
oversterfte-in-tweede-helft-2021-hoger-dan-covid-19-sterfte"
[5]#NU.nl, “RIVM en CBS stellen dat coronaprikken niet tot grotere sterftekans leiden”, https://
www.nu.nl/coronavirus/6208120/rivm-en-cbs-stellen-dat-coronaprikken-niet-tot-grotere-
sterftekans-leiden.html"
[6]#CBS (Dutch central bureau of statistics), "Overledenen per week, provincie en gemeente,
week 16, 2022”, https://www.cbs.nl/nl-nl/maatwerk/2022/17/overledenen-per-week-
provincie-en-gemeente-week-16-2022"
[7]#S. Ghisolfi et al., “Predicted COVID-19 fatality rates based on age, sex, comorbidities and
health system capacity”, British Medical Journal, Global Health, https://gh.bmj.com/
content/bmjgh/5/9/e003094.full.pdf"
[8]#H. Chemaitelly et al., “Duration of mRNA vaccine protection against SARS-CoV-2 Omicron
BA.1 and BA.2 subvariants in Qatar”, Nature. https://www.nature.com/articles/
s41467-022-30895-3"
[9]#Y. Goldberg, “Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2”, New
England Medical Journal, https://www.nejm.org/doi/full/10.1056/NEJMoa2118946"
[10]#C.S. Benn and F. Schaltz-Buchholzer, “Randomised Clinical Trials of COVID-19 Vaccines: Do
Adenovirus-Vector Vaccines Have Beneficial Non-Specific Eects?”, The Lancet preprint,
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4072489"
[11]#Fully-vaccinated coverage in Dutch municipalities, https://data.rivm.nl/data/covid-19/
COVID-19_vaccinatiegraad_per_gemeente_per_week_leeftijd.csv, downloaded November
2021"
[12]#Population size of Dutch municipalities, CBS, o.a. https://www.cbs.nl/nl-nl/maatwerk/
2022/10/voorlopige-bevolkingsaantallen-per-gemeente-1-1-2022"
[13]#Booster coverage in Dutch municipalities, https://coronadashboard.rijksoverheid.nl/
landelijk/vaccinaties, downloaded May 2022"
[14]#CBS (Dutch central bureau of statistics), “In mei oversterfte, behalve in de laatste week”,
https://www.cbs.nl/nl-nl/nieuws/2022/22/in-mei-oversterfte-behalve-in-de-laatste-week"
of 8 8
... Recently, several such excess mortality analyses have been made that are independent of existing national baselines and do not aim at forecasting, attempting to reduce subjectivity. In [Red1], a geographical-differential analysis was used, while [Red2,Red3] used a temporal-differential analysis effectively defining a baseline via a period around a moment in the past. In [Mee], a fixed baseline was estimated and used within the same analysis time frame. ...
... Time-since-full-vaccination (10 months total) If above VE's bare any relation with reality, one would expect that my results would show at least something remotely similar. Each of my four studies ([Red1,Red2,Red3] and the current, covering very different model approaches) finds the opposite: more vaccinations mean more mortality. The only similarity with Figure 28 is located at the end. ...
Preprint
Full-text available
A new mortality model is presented for more objective quantification and localization in time of excess mortality. The model is just one equation, M = W*atT, with source data of mortality and temperature. Parameters represent trends over decades, seasonal/weekly variability, delay between cause and death, frailty regulating delay between excess and deficit, lifetime lost/saved (LTL/LTS), and natural mortality variability. Pandemic excesses are examined by integrating determinants of positive covid tests and vaccinations. Measured parameters are covid Case Fatality Rate (CFR), Vaccine-dose Fatality Rate (VFR), Vaccine Effectivity (VE) against covid mortality, and LTL/LTS by covid and vaccination. Experiments involve 10 EU countries (344M people) and age-stratified datasets in The Netherlands over years 2000-2023. Predictions and excess measurements by the proposed model are fivefold more accurate than those of the national baseline. Covid is found to target much frailer people than natural causes do, and vaccine fatal events target younger and healthier people. Measured lifetime lost to vaccinations is of the same order as lifetime saved: Germany has LTL 450-4600ky (kiloyear), Netherlands 50-500ky. The model is very different from the state of the art and many options for further research are outlined. A disturbing relation is found between vaccinations and the persisting excess mortality among the young and healthy population. Keywords: Mortality, temperature, frailty, pandemic, excess, deficit, covid, vaccine, QALY, lifetime
... In other words, vaccines appear to have contributed (directly or indirectly) to an increase in other causes of death (than covid), in young populations. Those previous conclusions are now consistent with statistical results brought by a dozen of preprints and papers [1,3,5,16,19,20,28,30,33,34,38]. However, they are seemingly in contradiction with several major papers such as [26,42] as well as [6,21,22,41] that defend (based on all-cause mortality) a positive benet/risk balance. ...
Conference Paper
The question whether Covid-19 vaccination campaigns could have had an immediate negative impact on excess deaths continues to be debated two years later, in particular in the less than 45 years old. When the age-stratified (anonymized) vaccination status of deceased will be publicly available, the debate should come to an end. In the meantime, this paper provides three new statistical analyses that further shed light on the matter. Two of them connect the temporality of all-cause mortality data with injection data. Another analysis, using internet search trends, investigates possible alternative explanations. We deem that taken together, as it is done in this paper, those three analyses reinforce our previous conclusions suggesting caution when it comes to vaccinating/boosting young European populations. A preprint is available here: https://hdl.handle.net/2268/314674
... Several other studies have implicated COVID-19 vaccination in increased all-cause mortality. These studies have used different methods, countries, age groups, and time periods covering different COVID-19 variants, different vaccine histories, and time following vaccination [157][158][159][160][161][162][163]. A common theme is the involvement of mRNA vaccines, and poor outcomes in children and young adults. ...
Preprint
Full-text available
All vaccines exhibit both specific and non-specific effects. The specific effects are measured by the efficacy against the target pathogen, while the non-specific effects can be detected by the change in all-cause mortality. All-cause mortality data (gender, age band, vaccination history, month of death) between January 2021 and May 2022 was compiled by the Office for National Statistics. COVID-19 vaccination gave good protection on many occasions but less so for younger ages. Each gender and age group shows its own unique vaccination benefit/disbenefit time profile. Individuals are free to make vaccination decisions. For example, women aged 18-39 show a cohort who do not progress beyond the first or second dose. The all-cause mortality outcomes for the Omicron variant showed a very poor response to vaccination with 70% of sex/age/vaccination stage/month combinations increasing all-cause mortality, probably due to unfavorable antigenic distance between the first-generation vaccines and this variant, and additional non-specific effects. The all-cause mortality outcomes of COVID-19 vaccination is far more nuanced than have been widely appreciated, and virus vector appear better than the mRNA vaccines in this specific respect. The latter are seemingly more likely to increase all-cause mortality especially in younger age groups. An extensive discussion/literature review is included to provide potential explanations for the observed unexpected vaccine effects. Full text and Supplementary material at: https://www.preprints.org/manuscript/202304.0248/v1 Note that we are about to submit a version of this paper looking at the effects on non-COVID-19 all-cause mortality (NCACM).After that we aim to return to the all-cause mortality paper.
... In The Netherlands (population ~18M), excess mortality rates went up to ~80 people/day (excess ~20%) at end of 2022, before rising even more due to influenza. Based on the sparse publicly available Dutch data on mortality and vaccination, excess mortality was found to correlate positively with vaccination on long-term [Re1], and short-term [Mee,Sch,Re2]. Figure 1 illustrates this correlation for weekly 4th/5th vaccination campaign doses and all-cause mortality. ...
Article
Full-text available
This report investigates short-term causal vaccine-mortality interactions during booster campaigns in 2022 in 30 European countries (population ~530M). An infection-vaccination-mortality model is introduced with causal aspects of repeatability, random chance, temporal order and confounding. The model is simple, has few or even zero prior model parameters and is unbiased in causal mechanisms and strengths. Confounders are taken into account explicitly of mortality-caused fear incentivizing vaccinations and four related to covid infections, and generically for all long-term confounding. Bayesian probabilities quantify all interactions, and from observed weekly administered vaccine doses and all-cause mortality, mortality on short-term caused by a vaccination dose is estimated as Vaccine Fatality Ratio (VFR). VFR results are 0.13% (0.05%-0.21%, 95% confidence interval) in The Netherlands and 0.35% (0.15%-0.55%) in Europe, subtantially transcending covid IFR. Additionally, sewer-viral-particle experiments suggested vaccination induces covid-infections and/or reactivates latent viral reservoirs. The evidence of a causal relationship from vaccination to both infection and mortality is a very strong alarm signal to immediately stop current mass vaccination programmes.
Technical Report
Full-text available
This report investigates the natural variability of mortality, which determines the thin line between excesses and normal variation within expectations. I propose a model for mortality’s weekly variability based on a Poisson model, driven by potential non-stationary influences that act nation-wide and fast, on time scales of a week. Results reveal the presence of a significant amount of non-stationary influences that add to mortality’s weekly variability, with a magnitude of 3%±1% (1% - 5% with 95% confidence) times baseline mortality, on top of the standard (Poisson) variability. This additional variability is consistently found across 30 European countries (462M people) during 2017-2019. A long-term analysis in The Netherlands (17M people) reveals the same variability between 2010-2019, with substantial increase since 2020 to approx. 5%. Mortality variance may thus very well itself be used as event indicator when variability is higher than expected. The findings in this report are relevant for all models of mortality and its variability in general, and in particular for developments towards better excess mortality measurements. The additional variability found scales with both baseline mortality and population size in a different way compared to Poisson variability. For a typical mortality baseline of approx. 0.02% per week, the additional variability becomes dominant in populations above approximately 5M people. A number of causes for the variability found are suggested, of which the most promising, temperature, will be investigated in a follow-up to this report.
Research
Full-text available
This report proposes a new and simple method to measure vaccination-mortality correlation, test for causality, and if passed, obtain Vaccine Fatality Ratio (VFR), in the short-term of 0-4 weeks after vaccination. Only data of weekly administered number of doses and weekly all-cause-deaths are required, without reference to e.g. mortality prognoses, covid-labeled deaths or excess mortality. This report presents evidence of a short-term causal relation from 4th-dose covid-vaccination to mortality in The Netherlands, with a VFR of 0.18% corresponding to ca. 4400 vaccine-related deaths, in the order of magnitudes of covid IFR and observed excess mortality.
Article
Full-text available
SARS-CoV-2 Omicron BA.1 and BA.2 subvariants are genetically divergent. We conducted a matched, test-negative, case-control study to estimate duration of protection of the second and third/booster doses of mRNA COVID-19 vaccines against BA.1 and BA.2 infections in Qatar. BNT162b2 effectiveness was highest at 46.6% (95% CI: 33.4–57.2%) against symptomatic BA.1 and at 51.7% (95% CI: 43.2–58.9%) against symptomatic BA.2 infections in the first three months after the second dose, but declined to ~10% or below thereafter. Effectiveness rebounded to 59.9% (95% CI: 51.2–67.0%) and 43.7% (95% CI: 36.5–50.0%), respectively, in the first month after the booster dose, before declining again. Effectiveness against COVID-19 hospitalization and death was 70–80% after the second dose and >90% after the booster dose. mRNA-1273 vaccine protection showed similar patterns. mRNA vaccines provide comparable, moderate, and short-lived protection against symptomatic BA.1 and BA.2 Omicron infections, but strong and durable protection against COVID-19 hospitalization and death.
Article
Full-text available
The BNT162b2 mRNA vaccine is highly effective against SARS-CoV-2. However, apprehension exists that variants of concern (VOCs) may evade vaccine protection, due to evidence of reduced neutralization of the VOCs B.1.1.7 and B.1.351 by vaccine sera in laboratory assays. We performed a matched cohort study to examine the distribution of VOCs in infections of BNT162b2 mRNA vaccinees from Clalit Health Services (Israel) using viral genomic sequencing, and hypothesized that if vaccine effectiveness against a VOC is reduced, its proportion among breakthrough cases would be higher than in unvaccinated controls. Analyzing 813 viral genome sequences from nasopharyngeal swabs, we showed that vaccinees who tested positive at least 7 days after the second dose were disproportionally infected with B.1.351, compared with controls. Those who tested positive between 2 weeks after the first dose and 6 days after the second dose were disproportionally infected by B.1.1.7. These findings suggest reduced vaccine effectiveness against both VOCs within particular time windows. Our results emphasize the importance of rigorously tracking viral variants, and of increasing vaccination to prevent the spread of VOCs.
Article
Full-text available
Early reports suggest the fatality rate from COVID-19 varies greatly across countries, but non-random testing and incomplete vital registration systems render it impossible to directly estimate the infection fatality rate (IFR) in many low- and middle-income countries. To fill this gap, we estimate the adjustments required to extrapolate estimates of the IFR from high-income to lower-income regions. Accounting for differences in the distribution of age, sex and relevant comorbidities yields substantial differences in the predicted IFR across 21 world regions, ranging from 0.11% in Western Sub-Saharan Africa to 1.07% for high-income Asia Pacific. However, these predictions must be treated as lower bounds in low- and middle-income countries as they are grounded in fatality rates from countries with advanced health systems. To adjust for health system capacity, we incorporate regional differences in the relative odds of infection fatality from childhood respiratory syncytial virus. This adjustment greatly diminishes but does not entirely erase the demography-based advantage predicted in the lowest income settings, with regional estimates of the predicted COVID-19 IFR ranging from 0.37% in Western Sub-Saharan Africa to 1.45% for Eastern Europe.
COVID-19 vaccinations and mortality -a Bayesian analysis
  • R Meester
  • W Aukema
  • T Schetters
R. Meester, W. Aukema and T. Schetters, "COVID-19 vaccinations and mortality -a Bayesian analysis", https://www.researchgate.net/publication/ 357032975_COVID-19_vaccinations_and_mortality_-_a_Bayesian_analysis
Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2
  • Y Goldberg
Y. Goldberg, "Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2", New England Medical Journal, https://www.nejm.org/doi/full/10.1056/NEJMoa2118946